A strong and present leadership is the anchor of our business..
Board of Directors
Therefore, we have carefully composed a solid board of directors with highly qualified directors each offering relevant knowledge to our business.
Peter Vinding,
Board Member
MORE
Has 20+ years of experience and is specialised within Regulatory Life Science, Healthcare, M&A and Corporate Law
Christian is also highly specialised in legal issues facing the pharmaceutical industry, and has represented multiple companies in issues such as GCP, GMP, GDP, Market Access and Marketing Compliane
Team leader in multiple large succesful transactions including listings and mergers within the pharmaceutical industry.
Troels Peter Troelsen,
Board Member
MORE
Charlotte Pahl, Director at Sobi AB, Global Medical Affairs, Hematology.
She has over 30 years of experience in the pharmaceutical industry gained while working for Sobi.
Charlotte Pahl has a wide range of international contacts and networks within the healthcare business, healthcare professionals and patients’ organisations.
Charlotte Pahl,
Board Member
MORE
Charlotte Pahl, Director at Sobi AB, Global Medical Affairs, Hematology.
She has over 30 years of experience in the pharmaceutical industry gained while working for Sobi.
Charlotte Pahl has a wide range of international contacts and networks within the healthcare business, healthcare professionals and patients’ organisations.
Management
Thomas Kaas Selsø,
CEO
MORE
TKS serves as CEO in Pharma Equity Group and in Reponex Pharmaceuticals.
TKS has more than 20 years of experience as CEO and CFO of various companies. He has extensive experience within all aspects of economy and accounting, including financial management, financial accounting (IFRS & ÅRL), strategic analysis, M&A, valuation, and due diligence. He has worked for different listed companies such as Lex Invest, Foreningen Fast Ejendom and DSV and for private equity funds such as Polaris and Maj-Invest. TKS has previously also been appointed by Kromann Reumert and Danske Bank as a board member in the reconstruction of the clothing company Moss Copenhagen and has previously been appointed by Jyske Bank in a financially distressed case.
TKS has previously been CFO at North Risk, a Private Equity fund owned group of companies. Throughout his career as CFO and management consultant he has gotten a great understanding of business and extensive national and international experiences within multiple industries.
He has more than 17 years of experience as associate professor at the Copenhagen Business School (CBS), teaching in Accountancy (IFRS & ÅRL)) and M&A, among others, at different levels (MBA, CMA, HA, HD(R)).
Christopher Burton,
Chief Medical Officer
MORE
Christopher Burton, English nationality, has been the CMO of Reponex Pharmaceutical A/S’ since June 1, 2023. Christopher is an accomplished and results-driven industry physician with extensive experience in clinical research and development, as our new Chief Medical Officer, CMO, and an important addition to Reponex senior management team.
Dr Burton brings a wealth of expertise in developing strategies for pharmaceutical products, encompassing all phases of development from discovery to market. His professional medical career spans 25 years, having qualified as a medical doctor from Imperial College, London in 1998. Dr Burton worked for several years in clinical medicine to the level of registrar, is a Member of the Royal College of Physicians, and has international clinical experience from working in hospitals in England, Australia, and Denmark. He subsequently completed a PhD in transplant immunology at University of Copenhagen, before transitioning to the pharmaceutical industry in 2007.
During his industry career, Dr Burton has experience from both large and mid-sized pharmaceutical companies (Novo Nordisk and ALK), as well as small MedTech and biotech companies. Dr Burton has also provided clinical development and medical affairs consultancy services to a wide range of pharmaceutical clients supporting global, regional, or national initiatives across a range of therapeutic indications linked to inflammation, immunology, metabolic disease, and haematological and solid organ malignant disease. He has previously been involved in the development and commercialization of global brands and has a global network and contacts with key opinion leaders and pharmaceutical industry professionals.
Lars Skriver,
Chief Operation Officer
MORE
Biochemistry, Protein Research and Industry background.
Lars Skriver is a highly experienced professional with a strong background in biochemistry, boasting over 40 years of expertise in lipid and protein chemistry.
With over three decades of dedicated service in the pharmaceutical industry, he has held key leadership roles, including serving as the Co-founder and Managing Director at L&K Bioscience and as the COO at Serendex Pharmaceuticals A/S.
Prior to that, Lars contributed his knowledge as a Senior Science Officer at Savara Pharmaceuticals and gained valuable experience through various pharmaceutical development positions at Novo Nordisk A/S. His wealth of experience encompasses extensive expertise in Chemistry, Manufacturing, and Controls (CMC), making him a valuable asset to the field
Lars Otto Uttenthal,
Chief Scientific Officer
Lars Otto Uttenthal,
Chief Scientific Officer
MORE
Lars Otto Uttenthal (Dr. Phil. Oxford) brings a wealth of expertise to the table with a distinguished career spanning over 45 years in clinical medicine and biomedical research.
With a strong academic background, he has previously conducted research at renowned institutions such as the Universities of Oxford, London and Madrid, and held the position of Professor of Biochemistry at the University of Salamanca.
In addition to his impressive research background, Dr. Uttenthal has over 22 years of experience in leading research and development efforts within the medical industry.
Notably, he excels in the domain of intellectual property, having successfully conceived a considerable number of patent applications and navigated them through the application process, making him a valuable asset in the world of innovative healthcare.
